Lefamulin for M. Genitalium Treatment Failures

Mycoplasma Genitalium Infection Clinical Trial

Official title:

Lefamulin for Mycoplasma Genitalium Treatment Failures in the US

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05111002
• Other study ID #: STUDY00012927
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: April 22, 2022
• Est. completion date: November 30, 2023

Study information

• Verified date: November 2023
• Source: University of Washington
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this drug study is to find out whether the antibiotic lefamulin (trade name Xenleta) will cure Mycoplasma genitalium infections that have not been cured by prior antibiotics while finding out whether it is more effective if the antibiotic doxycycline is taken first.

Description:

Study participants will be randomly chosen to receive either lefamulin alone or doxycycline followed by lefamulin in a 1:1 ratio. Each participant will receive 14 lefamulin pills or 14 doxycycline pills and 14 lefamulin pills in the mail and take them as directed for one week (each). Participants will collect one culture sample and one sample to confirm M. genitalium infection on the same day they take their first pill then mail the two samples to the laboratory. They will also answer questions about their symptoms, any side effects, and their behavior with their sex partners. Participants will collect samples two more times and answer questions three more times if they are randomly chosen to receive lefamulin alone or four more times if they are randomly chosen to receive doxycycline followed by lefamulin during the study. The study team will culture M. genitalium then determine minimum inhibitory concentrations (MICs) to three antibiotics (azithromycin, moxifloxacin, and lefamulin) to see whether it is resistant to any of these antibiotics. The study team will also test for M. genitalium to confirm whether the participants have an infection at baseline and see if lefamulin cured the infection upon completion of the lefamulin.

After 20 patients have been enrolled, the study team will conduct an interim analysis to assess futility. Futility will be defined as less than five percent probability that true efficacy is greater than or equal to 60 percent (i.e., less than or equal to three of the first 10 participants experience microbiologic cure). If neither lefamulin alone nor doxycycline followed by lefamulin meets criteria for futility, the study team will continue the study. If one regimen meets criteria for futility, the study team will drop the regimen that met the criteria for futility and continue to administer the other regimen to the remaining 20 participants. If both regimens meet criteria for futility, the study team will halt the study.

Study participants will be informed of their M. genitalium test of cure results. If the lefamulin does not cure the infection, the study physician will consult with the referring physician who will continue to treat the infection per clinic standard of care.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 12
• Est. completion date: November 30, 2023
• Est. primary completion date: November 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Physician referral

• Persistent symptomatic urogenital M. genitalium infection documented by any nucleic acid amplification test (NAAT) 14-90 days after completion of the prior antimicrobial regimen for M. genitalium

• Low risk of reinfection, defined as no unprotected sex with an untreated sex partner since completion of the prior antimicrobial regimen for M. genitalium

• Living in the United States

• Male or female sex at birth

• At least 18 years of age

• English-speaking

• Able to provide written informed consent

• Able to undergo a test to confirm M. genitalium infection at baseline and tests of cure 21-28 days and 42-47 days after completion of the lefamulin

• Referring physician willing and able to provide needed patient information

Exclusion Criteria:

• Rectal M. genitalium infection only

• Females with pelvic inflammatory disease (PID), pregnancy, or currently breastfeeding

• Females of reproductive age not on a highly effective method of contraception (i.e., intrauterine device (IUD), Nexplanon, progesterone only depot injection with last injection less than three months prior, oral contraceptive pill and last menstrual period less than 28 days prior)

• Known QT prolongation or ventricular arrhythmias including torsades de pointes

• Receiving concurrent drugs known to prolong QT interval (i.e., Class IA or III antiarrhythmics, antipsychotics, erythromycin, pimozide, moxifloxacin, tricyclic antidepressants)

• Receiving strong or moderate CYP3A or P-gp inducers, strong CYP3A or P-gp inhibitors, moderate CYP3A or P-gp inhibitors, or sensitive CYP3A4 substrates that prolong QT interval

• Moderate or severe liver impairment

• Known liver disease

• Renal failure requiring dialysis

• Known allergy to doxycycline, other tetracyclines, and/or lefamulin

• Unwilling or unable to undergo a test to confirm M. genitalium infection at baseline or tests of cure 21-28 days and 42-47 days after completion of the lefamulin

• Not fluent in English and/or not able to provide written informed consent

• Referring physician unwilling or unable to provide needed patient information

• At the study physician's discretion

Related Conditions & MeSH terms

• Mycoplasma Genitalium Infection
• Mycoplasma Infections
• Pleuropneumonia

Intervention

Drug:
• Lefamulin
600mg tablet orally twice daily
• Doxycycline
100mg tablet orally twice daily

Locations

Country	Name	City	State
United States	University of Washington	Seattle	Washington

Sponsors (2)

Lead Sponsor	Collaborator
University of Washington	Nabriva Therapeutics AG

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Microbiologic cure	Defined as a negative Aptima Mycoplasma genitalium test 21-28 days after completion of the lefamulin	21-28 days after completion of the lefamulin
Secondary	Microbiologic cure after lefamulin alone compared to microbiologic cure after doxycycline followed by lefamulin	Defined as a negative Aptima Mycoplasma genitalium test 21-28 days after completion of the lefamulin	21-28 days after completion of the lefamulin
Secondary	Clinical cure	Defined as the absence of symptoms, visible discharge, and other clinical signs (e.g., less than 5 PMNs/HPF on Gram stained smear where available) 21-28 days after completion of the lefamulin	21-28 days after completion of the lefamulin
Secondary	Reported adherence to lefamulin	Defined by self-reported number of tablets taken	7 days from initial study start if randomized to lefamulin alone; 14 days from initial study start if randomized to lefamulin and doxycycline
Secondary	Reported adverse events	Defined by self-reported adverse events	42 days from initial study start if randomized to lefamulin alone; 49 days from initial study start if randomized to lefamulin and doxycycline
Secondary	Sustained microbiologic cure	Defined as a negative Aptima Mycoplasma genitalium test 42-47 days after completion of the lefamulin	42-47 days after completion of the lefamulin